{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T02:00:47Z","timestamp":1772244047907,"version":"3.50.1"},"reference-count":72,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2009.0312","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T05:12:39Z","timestamp":1525237959000},"source":"Crossref","is-referenced-by-count":2,"title":["The Treatment of Wet Age-Related Macular Degeneration"],"prefix":"10.3238","author":[{"given":"Antonia M.","family":"Joussen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Bornfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11437","published-online":{"date-parts":[[2009,5,1]]},"reference":[{"key":"10.3238\/arztebl.2009.0312_ref1","unstructured":"Spiro T: Luc(ifer)entis. Dtsch Arztebl 2007; 104(28\u201329): A2033."},{"key":"10.3238\/arztebl.2009.0312_ref2","unstructured":"Klein R, Wang Q, Klein BE, Moss SE, Meuer SM: The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity. Invest Ophthalmol Vis Sci 1995; 36: 182\u201391."},{"key":"10.3238\/arztebl.2009.0312_ref3","doi-asserted-by":"crossref","unstructured":"Schrader WF: Altersbedingte Makuladegeneration: eine sozio\u00f6konomische Zeitbombe in unserer alternden Gesellschaft. Ophthalmologe 2006; 103: 742\u20138.","DOI":"10.1007\/s00347-006-1418-4"},{"key":"10.3238\/arztebl.2009.0312_ref4","doi-asserted-by":"crossref","unstructured":"Sarks SH, Arnold JJ, Killingsworth MC, Sarks JP: Early drusen formation in the normal and aging eye and their relation to age related maculopathy: a clinicopathological study. Br J Ophthalmol 1999; 83: 358\u201368.","DOI":"10.1136\/bjo.83.3.358"},{"key":"10.3238\/arztebl.2009.0312_ref5","doi-asserted-by":"crossref","unstructured":"de Jong PT: Age-related macular degeneration. N Engl J Med 2006; 355: 1474\u201385.","DOI":"10.1056\/NEJMra062326"},{"key":"10.3238\/arztebl.2009.0312_ref6","doi-asserted-by":"crossref","unstructured":"Pauleikhoff D, Bornfeld N, Gabel VP, Holz F, Roider H: Konsenspapier der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbandes der Augen\u00e4rzte \u2013 Stellungnahme zur aktuellen Therapie der neovaskul\u00e4ren AMD. Klin Monatsbl Augenheilkd 2005; 222: 381\u20138.","DOI":"10.1055\/s-2005-858225"},{"key":"10.3238\/arztebl.2009.0312_ref7","unstructured":"Position of the Retinological Society, the German Ophthalmological Society and the Professional Association of Ophthalmologists in Germany on the current therapeutic possibilities for neovascular age-related macular degeneration. Klin Monatsbl Augenheilkd 2007; 224: 559\u201366."},{"key":"10.3238\/arztebl.2009.0312_ref8","doi-asserted-by":"crossref","unstructured":"Wormald R, Evans J, Smeeth L, Henshaw K: Photodynamic therapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2005 Oct 19; (4): CD002030. Review. Update in: Cochrane Database Syst Rev. 2007; (3): CD002030.","DOI":"10.1002\/14651858.CD002030.pub2"},{"key":"10.3238\/arztebl.2009.0312_ref9","doi-asserted-by":"crossref","unstructured":"Folkman J: Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972; 175: 409\u201316.","DOI":"10.1097\/00000658-197203000-00014"},{"key":"10.3238\/arztebl.2009.0312_ref10","unstructured":"Miller JW, Adamis AP, Shima DT, D'Amore PA, Moulton RS et al.: Vascular endothelial growth factor\/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994; 145: 574\u201384."},{"key":"10.3238\/arztebl.2009.0312_ref11","doi-asserted-by":"crossref","unstructured":"Chakravarthy U, Adamis AP, Cunningham ET Jr. et al.: Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 1508 e1\u2013e25.","DOI":"10.1016\/j.ophtha.2006.02.064"},{"key":"10.3238\/arztebl.2009.0312_ref12","doi-asserted-by":"crossref","unstructured":"Jaissle GB, Szurman P, Bartz-Schmidt KU: Empfehlung f\u00fcr die Durchf\u00fchrung von intravitrealen Injektionen \u2013 Stellungnahme der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft (DOG) und des Berufsverbands der Augen\u00e4rzte Deutschland (BVA). Klin Monatsbl Augenheilkd 2005; 222: 390\u20135.","DOI":"10.1055\/s-2005-858231"},{"key":"10.3238\/arztebl.2009.0312_ref13","doi-asserted-by":"crossref","unstructured":"Brown DM, Kaiser PK, Michels M et al.: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432\u201344.","DOI":"10.1056\/NEJMoa062655"},{"key":"10.3238\/arztebl.2009.0312_ref14","doi-asserted-by":"crossref","unstructured":"Rosenfeld PJ, Brown DM, Heier JS et al.: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419\u201331.","DOI":"10.1056\/NEJMoa054481"},{"key":"10.3238\/arztebl.2009.0312_ref15","doi-asserted-by":"crossref","unstructured":"Heiduschka P, Fietz H, Hofmeister S et al.: T\u00fcbingen Bevacizumab Study Group: Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007; 48: 2814\u201323.","DOI":"10.1167\/iovs.06-1171"},{"key":"10.3238\/arztebl.2009.0312_ref16","doi-asserted-by":"crossref","unstructured":"Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ: Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 363\u201372 e5.","DOI":"10.1016\/j.ophtha.2005.11.019"},{"key":"10.3238\/arztebl.2009.0312_ref17","doi-asserted-by":"crossref","unstructured":"Schouten JS, La Heij EC, Webers CA, Lundqvist IJ, Hendrikse F: A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2009; 247: 1\u201311.","DOI":"10.1007\/s00417-008-0952-y"},{"key":"10.3238\/arztebl.2009.0312_ref18","doi-asserted-by":"crossref","unstructured":"Fung AE, Rosenfeld PJ, Reichel E: The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006; 90: 1344\u20139.","DOI":"10.1136\/bjo.2006.099598"},{"key":"10.3238\/arztebl.2009.0312_ref19","doi-asserted-by":"crossref","unstructured":"Chan CK, Meyer CH, Gross JG et al.: Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Retina 2007; 27: 541\u201351.","DOI":"10.1097\/IAE.0b013e3180cc2612"},{"key":"10.3238\/arztebl.2009.0312_ref20","doi-asserted-by":"crossref","unstructured":"Bakri SJ, Kitzmann AS: Retinal pigment epithelial tear after intravitreal ranibizumab. Am J Ophthalmol 2007; 143: 505\u20137.","DOI":"10.1016\/j.ajo.2006.11.047"},{"key":"10.3238\/arztebl.2009.0312_ref21","doi-asserted-by":"crossref","unstructured":"Bressler SB, Childs AL, Haller JA et al.: Submacular Surgery Trials (SST) Research Group: Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings: SST report no. 13. Ophthalmology 2004; 111: 1993\u20132006.","DOI":"10.1016\/j.ophtha.2004.07.023"},{"key":"10.3238\/arztebl.2009.0312_ref22","unstructured":"Kim I, Ryan AM, Rohan R et al.: Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. Invest Ophthalmol Vis Sci 1999; 40: 2115\u201321. Erratum in: Invest Ophthalmol Vis Sci 2000; 41: 368."},{"key":"10.3238\/arztebl.2009.0312_ref23","doi-asserted-by":"crossref","unstructured":"Lux A, Llacer H, Heussen FM, Joussen AM: Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. Br J Ophthalmol 2007; 91: 1318\u201322.","DOI":"10.1136\/bjo.2006.113902"},{"key":"10.3238\/arztebl.2009.0312_ref24","unstructured":"PubMed-Suche 1998\u20132008; durchgef\u00fchrt 8\/2008."},{"key":"10.3238\/arztebl.2009.0312_ref25","doi-asserted-by":"crossref","unstructured":"Klaver CC, Wolfs RC, Vingerling JR, Hofman A, de Jong PT: Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch Ophthalmol 1998; 116: 653\u20138.","DOI":"10.1001\/archopht.116.5.653"},{"key":"10.3238\/arztebl.2009.0312_ref26","unstructured":"Vinding T: Age-related macular degeneration. An epidemiological study of 1000 elderly individuals. With reference to prevalence, funduscopic findings, visual impairment and risk factors. Acta Ophthalmol Scand Suppl 1995; 217: 1\u201332."},{"key":"10.3238\/arztebl.2009.0312_ref27","doi-asserted-by":"crossref","unstructured":"Friedmann DS, O-Colmain BJ, Munoz B et al.: Eye Diseases Prevalence Research Group: Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004; 122: 564\u201372.","DOI":"10.1001\/archopht.122.4.564"},{"key":"10.3238\/arztebl.2009.0312_ref28","doi-asserted-by":"crossref","unstructured":"Joeres S, Heussen FM, Treziak T, Bopp S, Joussen AM: Bevacizumab (Avastin) treatment in patients with retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol 2007; 245: 1597\u2013602.","DOI":"10.1007\/s00417-007-0580-y"},{"key":"10.3238\/arztebl.2009.0312_ref29","doi-asserted-by":"crossref","unstructured":"Joussen AM, Joeres S, Fawzy N et al.: Autologous translocation of the choroid and retinal pigment epithelium in patients with geographic atrophy. Ophthalmology 2007; 114: 551\u201360.","DOI":"10.1016\/j.ophtha.2006.08.016"},{"key":"10.3238\/arztebl.2009.0312_ref30","doi-asserted-by":"crossref","unstructured":"Evans JR, Henshaw K: Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration. Cochrane Database Syst Rev 2008; 1: CD000253. Review.","DOI":"10.1002\/14651858.CD000253.pub2"},{"key":"10.3238\/arztebl.2009.0312_ref31","doi-asserted-by":"crossref","unstructured":"Vedula SS, Krzystolik MG: Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2008; 16: CD005139.","DOI":"10.1002\/14651858.CD005139.pub2"},{"key":"10.3238\/arztebl.2009.0312_ref32","doi-asserted-by":"crossref","unstructured":"Macular Photocoagulation Study Group: Argon laser photocoagulation for senile macular degeneration. Five year results from randomized clinical trials. Arch Ophthalmol 1991; 109: 1109\u201314.","DOI":"10.1001\/archopht.1991.01080080069030"},{"key":"10.3238\/arztebl.2009.0312_ref33","doi-asserted-by":"crossref","unstructured":"Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularisation in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials \u2013 TAP Report 1: Arch Ophthalmol 1999; 117: 1329\u201345.","DOI":"10.1001\/archopht.117.10.1329"},{"key":"10.3238\/arztebl.2009.0312_ref34","doi-asserted-by":"crossref","unstructured":"Verteporfin in Photodynamic Therapy Report 2: Verteporfin therapy of subfoveal choroidal neovascularisation in age-related macular degeneration: two year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularisation. An J Ophthalmol 2001; 131: 541\u201360.","DOI":"10.1016\/S0002-9394(01)00967-9"},{"key":"10.3238\/arztebl.2009.0312_ref35","doi-asserted-by":"crossref","unstructured":"Wickens J, Blinder KJ: A preliminary benefit-risk assessment of verteporfin in age-related macular degeneration. Drug Saf 2006; 29: 189\u201399.","DOI":"10.2165\/00002018-200629030-00003"},{"key":"10.3238\/arztebl.2009.0312_ref36","doi-asserted-by":"crossref","unstructured":"Adamis AP, Shima DT, Tolentino MJ et al.: Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996; 114: 66\u201371.","DOI":"10.1001\/archopht.1996.01100130062010"},{"key":"10.3238\/arztebl.2009.0312_ref37","doi-asserted-by":"crossref","unstructured":"Aiello LP, Northrup JM, Keyt BA, Takagi H, Iwamoto MA: Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 1995; 113: 1538\u201344.","DOI":"10.1001\/archopht.1995.01100120068012"},{"key":"10.3238\/arztebl.2009.0312_ref38","doi-asserted-by":"crossref","unstructured":"Gonzales CR: Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. Retina 2005; 25: 815\u201327.","DOI":"10.1097\/00006982-200510000-00001"},{"key":"10.3238\/arztebl.2009.0312_ref39","doi-asserted-by":"crossref","unstructured":"Gragoudas ES, Adamis AP, Cunningham ET Jr., Feinsod M, Guyer DR: Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805\u201316.","DOI":"10.1056\/NEJMoa042760"},{"key":"10.3238\/arztebl.2009.0312_ref40","doi-asserted-by":"crossref","unstructured":"Calvo-Gonz\u00e1lez C, Reche-Frutos J, Donate-L\u00f3pez J et al.: Combined Pegaptanib sodium (Macugen) and photodynamic therapy in predominantly classic juxtafoveal choroidal neovascularisation in age related macular degeneration. Br J Ophthalmol 2008; 92: 74\u20135.","DOI":"10.1136\/bjo.2007.128942"},{"key":"10.3238\/arztebl.2009.0312_ref41","doi-asserted-by":"crossref","unstructured":"Fung AE, Lalwani GA, Rosenfeld PJ et al.: An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143: 566\u201383.","DOI":"10.1016\/j.ajo.2007.01.028"},{"key":"10.3238\/arztebl.2009.0312_ref42","doi-asserted-by":"crossref","unstructured":"Spaide R: Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol 2007; 143: 679\u201380.","DOI":"10.1016\/j.ajo.2007.02.024"},{"key":"10.3238\/arztebl.2009.0312_ref43","doi-asserted-by":"crossref","unstructured":"Chen Y, Wiesmann C, Fuh G et al.: Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 1999; 293: 865\u201381.","DOI":"10.1006\/jmbi.1999.3192"},{"key":"10.3238\/arztebl.2009.0312_ref44","doi-asserted-by":"crossref","unstructured":"Shahar J, Avery RL, Heilweil G et al.: Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006; 26: 262\u20139.","DOI":"10.1097\/00006982-200603000-00002"},{"key":"10.3238\/arztebl.2009.0312_ref45","doi-asserted-by":"crossref","unstructured":"Chen CY, Wong TY, Heriot WJ: Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study. Am J Ophthalmol 2007; 143: 510\u20132.","DOI":"10.1016\/j.ajo.2006.10.004"},{"key":"10.3238\/arztebl.2009.0312_ref46","doi-asserted-by":"crossref","unstructured":"Aisenbrey S, Ziemssen F, Volker M et al.: Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2007; 245: 941\u20138.","DOI":"10.1007\/s00417-006-0471-7"},{"key":"10.3238\/arztebl.2009.0312_ref47","doi-asserted-by":"crossref","unstructured":"Jonas JB, Libondi T, Ihloff AK et al.: Visual acuity change after intravitreal bevacizumab for exudative age-related macular degeneration in relation to subfoveal membrane type. Acta Ophthalmol Scand 2007; 85: 563\u20135.","DOI":"10.1111\/j.1600-0420.2007.00891.x"},{"key":"10.3238\/arztebl.2009.0312_ref48","unstructured":"www.fda.gov\/MedWatch\/safety\/2007\/Lucentis_DHCP_01-24-2007.pdf"},{"key":"10.3238\/arztebl.2009.0312_ref49","doi-asserted-by":"crossref","unstructured":"Liew G, Mitchell P: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2007; 356: 747\u20138; author reply 749\u201350.","DOI":"10.1056\/NEJMc063011"},{"key":"10.3238\/arztebl.2009.0312_ref50","doi-asserted-by":"crossref","unstructured":"Mennel S, Callizo J, Schmidt JC, Meyer CH: Acute retinal pigment epithelial tear in the untreated fellow eye following repeated bevacizumab (Avastin) injections. Acta Ophthalmol Scand 2007; 85: 689\u201391.","DOI":"10.1111\/j.1600-0420.2007.00926.x"},{"key":"10.3238\/arztebl.2009.0312_ref51","unstructured":"Comparison of Age-Related Macular Generation Treatment Trial (CATT): http:\/\/www.med.upenn.edu\/cpob\/studies\/CATT.shtml"},{"key":"10.3238\/arztebl.2009.0312_ref52","doi-asserted-by":"crossref","unstructured":"Raftery J, Clegg A, Jones J, Tan SC, Lotery A: Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol 2007; 91: 1244\u20136 .","DOI":"10.1136\/bjo.2007.116616"},{"key":"10.3238\/arztebl.2009.0312_ref53","doi-asserted-by":"crossref","unstructured":"Chaudhary V, Mao A, Hooper PL, Sheidow TG: Triamcinolone acetonide as adjunctive treatment to verteporfin in neovascular age-related macular degeneration: a prospective randomized trial. Ophthalmology 2007; 114: 2183\u20139.","DOI":"10.1016\/j.ophtha.2007.02.013"},{"key":"10.3238\/arztebl.2009.0312_ref54","doi-asserted-by":"crossref","unstructured":"Liggett PE, Colina J, Chaudhry NA, Tom D, Haffner G: Triple therapy of intravitreal triamcinolone, photodynamic therapy, and pegaptanib sodium for choroidal neovascularization. Am J Ophthalmol 2006; 142: 1072\u20134.","DOI":"10.1016\/j.ajo.2006.07.029"},{"key":"10.3238\/arztebl.2009.0312_ref55","doi-asserted-by":"crossref","unstructured":"Augustin AJ, Puls S, Offermann I: Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 2007; 27: 133\u201340.","DOI":"10.1097\/IAE.0b013e3180323de7"},{"key":"10.3238\/arztebl.2009.0312_ref56","doi-asserted-by":"crossref","unstructured":"Aisenbrey S, Lafaut BA, Szurman P et al.: Macular translocation with 360 degrees retinotomy for exudative age-related macular degeneration. Arch Ophthalmol. 2002; 120: 451\u20139.","DOI":"10.1001\/archopht.120.4.451"},{"key":"10.3238\/arztebl.2009.0312_ref57","doi-asserted-by":"crossref","unstructured":"Joussen AM, Heussen FM, Joeres S et al.: Autologous translocation of the choroid and retinal pigment epithelium in age-related macular degeneration. Am J Ophthalmol 2006; 142: 17\u201330.","DOI":"10.1016\/j.ajo.2006.01.090"},{"key":"10.3238\/arztebl.2009.0312_ref58","doi-asserted-by":"crossref","unstructured":"Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials\u2014TAP report. Arch Ophthalmol 1999;117(10): 1329\u201345.","DOI":"10.1001\/archopht.117.10.1329"},{"key":"10.3238\/arztebl.2009.0312_ref59","doi-asserted-by":"crossref","unstructured":"Chakravarthy U, Adamis AP, Cunningham ET Jr et al.: Clinical Trial Group:VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.). Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 1508. e1\u2013e25. Epub 2006; Jul 7.","DOI":"10.1016\/j.ophtha.2006.02.064"},{"key":"10.3238\/arztebl.2009.0312_ref60","unstructured":"http:\/\/www.nice.org.uk\/TA155"},{"key":"10.3238\/arztebl.2009.0312_ref61","doi-asserted-by":"crossref","unstructured":"D'Amico DJ, Goldberg MF, Hudson H et al.: Anecortave Acetate Clinical Study Group: Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical efficacy and safety. Retina 2003; 23: 14\u201323.","DOI":"10.1097\/00006982-200302000-00003"},{"key":"10.3238\/arztebl.2009.0312_ref62","doi-asserted-by":"crossref","unstructured":"Slakter JS: Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. Ophthalmology 2003; 110: 2372\u201383.","DOI":"10.1016\/j.ophtha.2003.08.020"},{"key":"10.3238\/arztebl.2009.0312_ref63","doi-asserted-by":"crossref","unstructured":"Slakter JS, Bochow TW, D'Amico DJ et al.: Anecortave Acetate Clinical Study Group: Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmology 2006; 113: 3\u201313.","DOI":"10.1016\/j.ophtha.2005.10.019"},{"key":"10.3238\/arztebl.2009.0312_ref64","doi-asserted-by":"crossref","unstructured":"Klais CM, Eandi CM, Ober MD et al.: Anecortave acetate treatment for retinal angiomatous proliferation: a pilot study. Retina 2006; 26: 773\u20139.","DOI":"10.1097\/01.iae.0000244261.52901.67"},{"key":"10.3238\/arztebl.2009.0312_ref65","doi-asserted-by":"crossref","unstructured":"Klais CM, Eandi CM, Ober MD et al.: Anecortave acetate for the treatment of idiopathic perifoveal telangiectasia: a pilot study. Retina 2006: 26: 780\u20135.","DOI":"10.1097\/01.iae.0000244262.91018.4d"},{"key":"10.3238\/arztebl.2009.0312_ref66","doi-asserted-by":"crossref","unstructured":"Kuppermann BD, Blumenkranz MS, Haller JA et al.: Dexamethasone DDS Phase II Study Group. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007; 125: 309\u201317.","DOI":"10.1001\/archopht.125.3.309"},{"key":"10.3238\/arztebl.2009.0312_ref67","doi-asserted-by":"crossref","unstructured":"Nguyen QD, Shah SM, Hafiz G et al.: CLEAR-AMD 1 Study Group: a Phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006; 113: 1522 e1\u2013e14.","DOI":"10.1016\/j.ophtha.2006.05.055"},{"key":"10.3238\/arztebl.2009.0312_ref68","doi-asserted-by":"crossref","unstructured":"Shen J, Samul R, Silva RL et al.: Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther 2006; 13: 225\u201334.","DOI":"10.1038\/sj.gt.3302641"},{"key":"10.3238\/arztebl.2009.0312_ref69","doi-asserted-by":"crossref","unstructured":"Campochiaro PA, Nguyen QD, Shah SM et al.: Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a Phase I clinical trial. Hum Gene Ther 2006; 17: 167\u201376.","DOI":"10.1089\/hum.2006.17.167"},{"key":"10.3238\/arztebl.2009.0312_ref70","doi-asserted-by":"crossref","unstructured":"Brafman A, Mett I, Shafir M et al.: Inhibition of oxygen-induced retinopathy in RTP801-deficient mice. Invest Ophthalmol Vis Sci 2004; 45: 3796\u2013805.","DOI":"10.1167\/iovs.04-0052"},{"key":"10.3238\/arztebl.2009.0312_ref71","doi-asserted-by":"crossref","unstructured":"Lima e Silva R, Kachi S, Akiyama H et al.: Transscleral delivery of polyamine analogs for ocular neovascularization. Exp Eye Res 2006; 83: 1260\u20137.","DOI":"10.1016\/j.exer.2006.07.003"},{"key":"10.3238\/arztebl.2009.0312_ref72","doi-asserted-by":"crossref","unstructured":"Lima e Silva R, Saishin Y, Saishin Y et al.: Suppression and regression of choroidal neovascularization by polyamine analogues. Invest Ophthalmol Vis Sci 2005; 46: 3323\u201330.","DOI":"10.1167\/iovs.04-1210"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2009.0312","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T04:34:33Z","timestamp":1638851673000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2009.0312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,1]]},"references-count":72,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2009.0312","relation":{"is-cited-by":[{"id-type":"doi","id":"10.1155\/2013\/830837","asserted-by":"object"}]},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,1]]}}}